OCRA News

OCRA Now Accepting Applications for 2021 Research Grants

(June 11, 2020) Letters of Intent (LOIs) for Ovarian Cancer Research Alliance’s 2021 scientific grant awards are now open for submission. LOIs are due by July 10, 2020. Accepting LOIs is step one of OCRA’s highly competitive grant process…

Read on

Connecting Survivors to the Science | Meet a Research Advocate

To speak with Kimberly Richardson is to feel an instant camaraderie with someone who exhibits both calm and conviction, thoughtfulness and frank talk…

Read on

Convenient Spit Test Helps Women Assess Cancer Risk From the Comfort of Their Own Home

First-of-its-kind clinical trial validates remote genetic counseling (New York) June 01, 2020 – Genetic testing for cancer risk can significantly improve the prevention or treatment of hereditary cancers, but studies have shown that people who…

Read on

A Statement from OCRA

If there’s one thing that working toward an end to ovarian cancer has taught us, it’s that life is precious. We value the life of every person in our ovarian cancer community, and celebrate its diversity and strength…

Read on

Inspired Advice: What Do You Need Most from a Life Partner?

Those who have faced an ovarian or gynecologic cancer diagnosis have so much to offer to others going through a similar experience – be it support, tips or friendship…

Read on

Speaking Out for Those Who Can’t | OCRA Advocate Leader

In 2005, Denise Lobodinski’s sister Renee was diagnosed with ovarian cancer at the age of 47. That same year, their father was diagnosed with prostate cancer. But her father’s doctor told Denise’s mother, “Don’t worry about your husband…

Read on

Survey: Navigating Treatment in the Time of Covid-19

Covid-19 has disrupted nearly every aspect of life as we know it, and navigating a diagnosis and treatment for ovarian cancer – already a game changer – has been impacted as well…

Read on

Science Made Simple: Ovarian Cysts and Ovarian Cancer

Ovarian cysts are fairly common, but that doesn’t make having them any less nerve-wracking. If you’ve been diagnosed with an ovarian cyst, it’s natural to wonder if that means you have, or are at risk of developing, ovarian cancer…

Read on

When a Virus is a Good Thing | Meet a Scientist

Scared. Overwhelmed. Exhausted. Befuddled.  These are common words one might use to describe how we feel during this unprecedented time in history…

Read on

Reflections from the Frontline | OCRA Scientists on Covid-19

We reached out to our grantees and Scientific Advisory Committee, many of whom are on the frontlines – working in hospitals, meeting with patients, seeing firsthand the impact of Covid-19. We wanted to hear their words and reflections…

Read on

Raising Awareness of the Unseen, Giving Voice to the Unheard | Survivor Stories

The world works in ironic and sometimes painful ways Yvette Jives, a nurse and social worker in North Carolina, has spent a lifetime helping others…

Read on

Niraparib Receives FDA Approval as First-Line Maintenance Therapy for Advanced Ovarian Cancer

(May 4, 2020) On April 29th, the Food and Drug Administration approved niraparib (Zejula, GlaxoSmithKline) as a first-line maintenance treatment for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, regardless of BRCA…

Read on